{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:16:44Z","timestamp":1780503404224,"version":"3.54.1"},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch med Wochenschr"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>End stage chronic kidney disease (CKD) requiring renal replacement therapy is related to poor quality of life and high mortality. Thus, slowing the progression of CKD is an important purpose of therapy. Some general therapeutic approaches aim to slow the decline of renal function and they can be applied in all patients with CKD \u2013 irrespective of the underlying cause of CKD. A key intervention is lowering blood pressure (target: \u2264\u200a140\/90\u200ammHg, and in patients with albuminuria \u2264\u200a130\/80\u200ammHg). Inhibitors of the renin angiotensin system preferentially should be used in case of albuminuria, depending on the diabetic status and the level of albuminuria: in diabetics with albuminuria \u2265\u200a30\u200amg\/d, in non-diabetics with albuminuria &gt;\u200a300\u200amg\/d. Mineralocorticoid receptor blockers and endothelin receptors blockers promise novel anti-proteinuric strategies \u2013 but still validation of their positive effects on retarding CKD progression is necessary. In patients with diabetic kidney disease, glycemic control aiming for an HbA1c of \u2248\u00a07.0\u200a% has been established to slow CKD progression. Furthermore, SGLT-2 inhibition with empagliflozin may be considered as a new therapeutic approach that provides additional cardiovascular and renal protection. Finally, recent studies suggest: correction of metabolic acidosis and avoidance of episodes of acute renal failure may provide protection against the progression of CKD.<\/jats:p>","DOI":"10.1055\/s-0042-115782","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T19:00:08Z","timestamp":1504033208000},"page":"1282-1289","source":"Crossref","is-referenced-by-count":2,"title":["Die Progression der Nierenerkrankung \u2013 wie ist sie zu verhindern?"],"prefix":"10.1055","volume":"142","author":[{"given":"Markus","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Hilgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,8,29]]},"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-115782.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T05:28:41Z","timestamp":1513661321000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-115782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":0,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2017,8,29]]},"published-print":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-115782","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]}}}